Heart transplantation increases quality of life and life expectancy in patients with end stage heart failure. Patients diagnosed with severe heart failure via cardiopulmonary function tests are candidates for heart transplantation. Immunosuppressive treatment administered after transplantation is a three-drug treatment method used to weaken the recipient’s immune system in order to prevent rejection of the transplanted organ. While early-term complications of heart transplant include primary graft incompatibility, right ventricular failure, and infections, malignancies and cardiac allograft vasculopathy (CAV) are among late-term complications. The past decade has revealed 50% increased incidence of post-transplant CAV which is difficult to diagnose and treat to this day.
Dergi Türü : Uluslararası
Benzer Makaleler | Yazar | # |
---|
Makale | Yazar | # |
---|